Výsledky vyhledávání

Akademický článek

The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity

Autor: Winston Stauffer, Michael Bobardt, Daren Ure, Robert Foster, Philippe Gallay

Publikováno v: Viruses, Vol 15, Iss 10, p 2099 (2023)

There is an urgent need for the identification of new drugs that inhibit HCV-induced hepatocellular carcinoma (HCC). Our work demonstrates that cyclophilin inhibitors (CypIs) represent such new drugs. We demonstrate that the nonimmunosuppressive cycl

Externí odkaz: https://doaj.org/article/7526b825a92349d892ee9d36646ce76a

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.

Autor: Michael Bobardt, Christina M Ramirez, Marc M Baum, Daren Ure, Robert Foster, Philippe A Gallay

Publikováno v: PLoS ONE, Vol 16, Iss 5, p e0251934 (2021)

We and others previously reported that the direct-acting agents (DAA) NS5A inhibitors (NS5Ai) and the host-targeting agents cyclophilin inhibitors (CypIs) inhibit HCV replication in vitro. In this study, we investigated whether the combination of NS5

Externí odkaz: https://doaj.org/article/fd6c7099ffba42e0862d69740429210b

Zobrazit plný text záznamu

Akademický článek

Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice.

Autor: Michael Bobardt, Magnus Joakim Hansson, Patrick Mayo, Daren Ure, Robert Foster, Philippe Gallay

Publikováno v: PLoS ONE, Vol 15, Iss 8, p e0237236 (2020)

We previously reported that the non-immunosuppressive cyclophilin inhibitors (CypIs)-cyclosporin A analog CRV431 and sanglifehrin analog NV556-efficiently inhibit HCV replication in vitro. In this study, we asked whether they can also reduce HCV repl

Externí odkaz: https://doaj.org/article/3f247589fc5b488c82f574f61cff82e6

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.

Autor: Philippe Gallay, Daren Ure, Michael Bobardt, Udayan Chatterji, James Ou, Daniel Trepanier, Robert Foster

Publikováno v: PLoS ONE, Vol 14, Iss 6, p e0217433 (2019)

Hepatitis B virus (HBV) infection is a major health burden worldwide with 240 million chronically infected individuals. Nucleos(t)ide analogs and interferons are the current standards of care due to their suppression of HBV replication, but the treat

Externí odkaz: https://doaj.org/article/3043b4e99c594fb88553cbc3157589bd

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.

Autor: Philippe A Gallay, Michael D Bobardt, Udayan Chatterji, Daniel J Trepanier, Daren Ure, Cosme Ordonez, Robert Foster

Publikováno v: PLoS ONE, Vol 10, Iss 8, p e0134707 (2015)

HCV-related liver disease is the main cause of morbidity and mortality of HCV/HIV-1 co-infected patients. Despite the recent advent of anti-HCV direct acting antivirals (DAAs), the treatment of HCV/HIV-1 co-infected patients remains a challenge, as t

Externí odkaz: https://doaj.org/article/1b8d9a0cbe4f47dfa9addb58a1c373d8

Zobrazit plný text záznamu

Effect of a High‐Fat Meal on Single‐Dose Rencofilstat (CRV431) Oral Bioavailability in Healthy Human Subjects

Autor: Ellen Remenchik, Patrick R. Mayo, Todd M. Hobbs, Jill A. Greytok, Erin P. Foster, Caroline Zhao, Daren Ure, Daniel J. Trepanier, Robert T. Foster

Publikováno v: Clinical Pharmacology in Drug Development. 12:287-293

Rencofilstat (RCF) is a novel cyclophilin inhibitor under development for the treatment of nonalcoholic steatohepatitis and hepatocellular carcinoma. This phase 1, randomized, open-label study in healthy participants assessed the relative bioavailabi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ad586c26890653250e180e71f7f5699
https://doi.org/10.1002/cpdd.1179

Zobrazit plný text záznamu

Abstract 4125: Rencofilstat exerts a dominant role in synergistic anti-PD1-combination effects in a fatty liver model of hepatocellular carcinoma

Autor: Daren Ure, Jack Leslie, Lacey Haddon, Claude Fu, Jelena Mann, Derek Mann

Publikováno v: Cancer Research. 83:4125-4125

Rencofilstat is a clinical-phase drug candidate that inhibits multiple cyclophilin isomerases and affects many cellular processes. The objectives of this study were to characterize rencofilstat’s anti-tumor effects alone and in combination with ant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::130d683baac28c3a4aeaf813f7afad18
https://doi.org/10.1158/1538-7445.am2023-4125

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání